Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system

Definitions

• FasL also called CD95L and APOIL
• FasL is expressed on various cell types and can produce biological responses such as proliferation, differentiation, immunoregulation, inflammatory response, cytotoxicity, and apoptosis .
• FasL the ligand for the TNFR- family receptor FAS/APO (Suda et al . , 1993, Cell 75:1169-78, are associated with autoimmunity (Fisher et al . , 1995, Cell 81:935-46; Wu et al . J. Clin. Invest. 5, 1107-1113, 1996), while overproduction of FasL may be implicated in acute lung injury ( atute-Bello et al .
• FasL is expressed in immune-privileged tissues of the eye, testis, brain and some tumors. It has also been found in kidney and lung as well as in activated thymocytes, splenocytes, and T lymphocytes.
• Apoptosis plays a central role in both development and in homeostasis.
• Cells die by apoptosis in the developing embryo during morphogenesis or synaptogenesis and in the adult animal during tissue turnover or at the end of an immune response.
• the physiological role of apoptosis is crucial, aberration of this process can be detrimental.
• unscheduled apoptosis of certain brain neurons contributes to disorders such as Alzheimer's and Parkinson's disease, whereas the failure of dividing cells to initiate apoptosis after sustaining severe DNA damage contributes to cancer.
• survival signals from the cell's environment and internal sensors for cellular integrity normally keep a cell's apoptotic machinery in check. In the event that a cell loses contact with its surroundings or sustains irreparable damage, the cell initiates apoptosis. A cell that simultaneously receives conflicting signals driving or attenuating its division cycle also triggers apoptosis. Mammals have evolved yet another mechanism that enables the organism actively to direct individual cells to self- destruct. This kind of "instructive" apoptosis is important especially in the immune system. Death receptors transmit apoptosis signals initiated by specific "death ligands" and play a central role in instructive apoptosis. These receptors can activate death caspases within, seconds of ligand binding, causing an apoptotic demise of the cell within hours.
• Death receptors belong to the tumor necrosis factor (TNF) receptor superfamily, which is defined by similar, cysteine-rich extracellular domains.
• TNF tumor necrosis factor
• the death receptors contain an additional cytoplasmic sequence termed the "death domain.” Death domains typically enable death receptors to engage the cell's apoptotic machinery, but in some instances they mediate functions that are distinct from or even counteract apoptosis.
• Fas (also called CD95 or Apol) is a well-characterized death receptor. Fas and Fas ligand (FasL) play an important role in apoptosis. FasL can form a homotrimeric molecule. It is suggested that each FasL trimer binds to and ligates three Fas molecules. Because death domains have a propensity to associate with one another, Fas ligation leads to clustering of the receptors' death domains. An adapter protein called FADD (Fas-associated death domain; also called Mortl) then binds through its own death domain to the clustered receptor death domains.
• FADD Fas-associated death domain
• FADD also contains a "death effector domain” that binds to an analogous domain repeated in tandem within the zymogen form of caspase-8 (also called FLICE, or MACH) .
• caspase-8 oligomerization drives its activation through self-cleavage .
• Caspase-8 then activates downstream effector caspases such as caspase-9 committing the cell to apoptosis.
• FasL triggers apoptosis in T lymphocytes, it is proinflammatory . FasL has been shown to stimulate neutrophils, also called polymorphonuclear leukocytes (PMNs) , activation. (Chen J. et at, Science 282: 1714-17 (1998) ) FasL-Fas binding has been implicated in clonal deletions of autoreactive lymphocytes in peripheral lymphoid tissues, resulting in elimination of autoreactive lymphocyte populations, thus contributing to homeostasis of the immune system. However, it has been found that expression of FasL on myotubes or pancreatic islets of transgenic mice induces a granulocytic response that accelerates graft rejection (Allison J.
• FasL-Fas receptor binding At least one of the effects of FasL-Fas receptor binding is apoptosis, which is necessary for homeostasis. However, sometimes the balance of FasL-Fas binding is upset in stress, disease or trauma. One of the negative effects of dysregulated FasL-Fas binding is "runaway" or aberrant apoptosis. Another potential effect of said binding is the destruction of healthy cells caused by neutrophils that have been activated by FasL.
• FLINT i.e. "FAS Ligand Inhibitory Protein
• FAS Ligand Inhibitory Protein binds FasL and LIGHT, also a member of the TNF family.
• LIGHT is a membrane-bound ligand that triggers a biological response that is distinct from the Fas-FasL pathway. LIGHT may play a role in immune modulation, and in herpes virus entry (see Zhai et al . , J. Clin. Invest. 102, 1142-1151, 1998; Montgomery et al . Cell, 87, 427-436, 1996). Soluble LIGHT inhibits the proliferation of various tumor cells whilst binding at least two receptors, LT ⁇ R and TR2 (also referred to as herpes virus entry mediator, HVEM) .
• LT ⁇ R and TR2 also referred to as herpes virus entry mediator, HVEM
• LIGHT is expressed highly in activated lymphocytes and evokes immune modulation from hematopoietic cells. For example, LIGHT stimulates the secretion of IFN ⁇ . LIGHT also induces apoptosis of tumor cells that express the LT ⁇ R and TR2/HVEM receptors. The cytotoxic effect of LIGHT is enhanced by IFN ⁇ , which can be blocked by addition of soluble LT ⁇ R-Fc or TR2/HVEM-Fc. There is evidence also to support a role for LIGHT in stimulating the proliferation of T cells (See e.g. J. A. Harrop et al . J. Biol . Chem. 273, 27548-556, 1998). Since FLINT binds
• LIGHT there is thereby a means to inhibit the stimulation of T cells for example as a means to prevent organ rejection following a transplant procedure.
• FLINT also interacts with FasL, thereby preventing the binding of FasL to Fas. At least one biological effect results on the binding of FLINT to FasL, namely, inhibition of apoptosis. Since many diseases are thought to involve the FasL-Fas pathway, or the LIGHT-mediated pathway, FLINT could provide a means to treat and/or prevent such diseases. Among the most devastating afflictions to the population of centuries include acute and chronic lung diseases that may involve abnormal apoptosis, for example, lung cancer, pulmonary fibrosis, acute lung injury, connective tissue diseases, drug-induced lung disease, chronic obstructive pulmonary disease and others.
• the invention relates to the use of FLINT in treating and/or inhibiting lung disorders, specifically, pulmonary fibrosis ("PF”), and chronic obstructive pulmonary disease (“COPD”), acute lung injury, connective tissue diseases, drug-induced lung disease, and others.
• PF pulmonary fibrosis
• COPD chronic obstructive pulmonary disease
• Further aspects of the invention include formulations, having FLINT as an active ingredient that are adapted for treating and/or inhibiting COPD, and PF . Further aspects of the invention include formulations, having FLINT as an active ingredient that are adapted for inhibiting T cell proliferation.
• Yet other embodiments of the invention include the use of FLINT in the preparation of medicaments useful in treating and/or inhibiting COPD, and PF .
• Yet other embodiments of the invention include the use of FLINT in the preparation of medicaments useful in inhibiting T cell proliferation.
• the invention includes a method of treating and/or inhibiting COPD in an individual comprising administration of a therapeutically effective amount of FLINT protein to said individual .
• the invention includes a method of treating and/or inhibiting pulmonary fibrosis in an individual comprising administration of a therapeutically amount of FLINT protein to said individual .
• the present invention relates to the use of FLINT to inhibit T lymphocyte activation.
• SEQ ID N0:1 Mature human FLINT, i.e. native FLINT minus the leader sequence.
• SEQ ID NO: 2 Nucleic acid/cDNA encoding mature human FLIN .
• SEQ ID NO: 4 Human FLINT leader sequence.
• SEQ ID NO: 5 Nucleic acid/cDNA encoding human FLINT.
• FLINT polypeptides are capable of disrupting the FasL-Fas receptor interaction which can cause or exacerbate a variety of diseases.
• Data presented below show that FLINT inhibits both FasL apoptosis-inducing activity and proinflammatory activity.
• FLINT polypeptides can modulate the destruction of healthy cells caused both by neutrophils activated by FasL and by apoptotic damage mediated directly by FasL-Fas interaction.
• the present methods of treatment utilizing FLINT are useful in the treatment and prevention and/or inhibition of disorders associated with the direct apoptotic effects of FasL and/or the damage mediated by the proinflammatory effects of FasL, whether or not these represent distinct physiological pathways.
• the invention relates to methods preventing or treating conditions caused or exacerbated by "abnormal apoptosis," in particular, apoptosis induced by Fas ligand (FasL) and Fas receptor (Fas) binding (also referred to as FasL-Fas binding) .
• This invention also relates to methods of preventing or treating conditions caused by a proinflammatory response, more particularly, a proinflammatory response caused by FasL induced neutrophil activation.
• the term "FLINT” refers to a FLINT polypeptide, for example, a full-length polypeptide including a leader sequence, for example SEQ ID NO: 3.
• the ter also refers to a FLINT polypeptide lacking a leader, for example SEQ ID NO:l.
• FasL or Fas expression or interaction As used here, with reference to FasL or Fas expression or interaction, and to any resulting apoptosis, the terms “inappropriate” and “abnormal” should be read to include any deviation from normal expression, interaction or apoptosis levels. Such deviations include temporal, quantitative and qualitative abnormalities. FasL or Fas "expression” refers not only transcription, translation and associated events, but also to any process that results in increased availability of active FasL or Fas, such as transport and/or cell surface availability/accessibility.
• abnormal apoptosis refers to excessive and/or improper apoptosis. Typically abnormal apoptosis is observed in cells and tissues that have undergone physical, chemical or biological insult.
• Such insults include, but are not limited to physical injury, viral infection, bacterial infection, ischemia, irradiation, chemotherapy, and the like.
• effective amount means an amount of FLINT is capable of treating and/or inhibiting ARDS, ALI, PF and/or
• fusion protein or FLINT fusion protein
• fusion protein denotes a hybrid protein molecule not found in nature comprising a translational fusion or enzymatic fusion in which two or more different proteins or fragments thereof are covalently linked on a single polypeptide chain comprising SEQ ID NO:l or SEQ ID NO : 3 , functional fragment thereof .
• "Host cell” refers to any eucaryotic or procaryotic cell that is suitable for propagating and/or expressing a cloned gene contained on a vector that is introduced into said host cell by, for example, transformation or transfection, or the like.
• inhibitor includes the generally accepted meaning, which includes prohibiting, preventing, restraining, slowing, stopping, or reversing progression or severity.
• isolated nucleic acid compound refers to any RNA or DNA sequence, however constructed or synthesized, which is locationally distinct from its natural location.
• Recombinant DNA cloning vector refers to any autonomously replicating agent, including, but not limited to, plasmids and phages, comprising a DNA molecule to which one or more additional DNA segments can or have been incorporated.
• expression vector refers to any recombinant DNA cloning vector, for example a plasmid or phage, in which a promoter and other regulatory elements are present thereby enabling transcription of an inserted DNA, which may encode a polypeptide .
• selective binding refers to the ability of FLINT polypeptides to bind FasL but not TNF°c .
• substantially pure used in reference to a peptide or protein means that said peptide or protein is separated from other cellular and non-cellular molecules, including other protein molecules.
• a substantially pure preparation would be about at least 85% pure; preferably about at least 95% pure.
• a "substantially pure” protein as described herein could be prepared by a variety of techniques well known to the skilled artisan, including, for example, the IMAC protein purification method.
• treatment or “treating” as used herein, describes the management and care of a patient for the purpose of combating a disease, condition, or disorder and includes the administration of FLINT to alleviate the symptoms or complications of said disease, condition, or disorder .
• vector refers to a nucleic acid compound used for introducing exogenous or endogenous DNA into host cells.
• a vector comprises a nucleotide sequence which may encode one or more protein molecules . Plasmids, cosmids, viruses, and bacteriophages, in the natural state or which have undergone recombinant engineering, are examples of commonly used vectors.
• COPD Chronic Obstructive Pulmonary Disease
• COPD chronic obstructive pulmonary disease
• COPD chronic obstructive pulmonary disease
• chronic bronchitis chronic bronchitis
• emphysema chronic bronchiectasis
• chronic asthma chronic asthma
• COPD chronic hypoxemia and hypercapnia are the eventual outcomes of the disorder.
• Plasma samples from patients suffering from COPD exhibit higher concentrations of soluble Fas compared with healthy control subjects (See Yasuda et al . Resp. Med. 92, 993-999, 1998) .
• the increased levels of soluble Fas in COPD patients may reflect increased Fas-induced apoptosis.
• the present invention relates to the use of FLINT to treat and/or inhibit COPD in a patient in need thereof by administering a therapeutically effective amount of FLINT.
• Pulmonary Fibrosis (PF) Pulmonary Fibrosis
• Pulmonary fibrosis also known as fibrosing lung disease
• Pulmonary fibrosis occurs as an end result of the process of attempted healing during acute or chronic lung injury.
• the pathological mechanism of such lung injury can be any of various factors that first trigger an inflammatory response in the alveoli or surrounding interstitium and subsequently trigger alveolar/interstitial fibrosis (i.e. the repair response) .
• Fibrosis in other tissues such as the epidermis or the peritoneum, leads to visible scarring or adhesions, respectively.
• Pulmonary fibrosis in contrast, leads to restrictive lung disease (decreased lung capacities and decreaased oxygen diffusion) .
• Conditions associated with pulmonary fibrosis include but are not limited to: idiopathic pulmonary fibrosis, connective tissue diseases (e.g. lupus, scleroderma) , drug-induced lung disease (e.g. bleomycin) , pneumoconioses (e.g. asbestosis) , sarcoidosis, eosinophilic granulomatosis , hypersensitivity pneumonitis, and other diseases asscoiated with severe lung inflammation that can result in acute lung injury and/or acute respiratory distress syndrome (e.g. trauma, sepsis, near- drowning, gastric aspiration, shock, etc.) . Fibrosis of the airways is also a feature of the chronic inflammation in COPD.
• connective tissue diseases e.g. lupus, scleroderma
• drug-induced lung disease e.g. bleomycin
• pneumoconioses e.g. asbestosis
• sarcoidosis e
• the etiology of PF may involve FasL/Fas-triggered apoptosis. Indeed, an intact FasL/Fas system is essential in the etiology of bleomycin-induced PF in mice (See Kuwano K. et al. J. Clin. Invest. 104, 13-19 (1999).
• the present invention relates to the use of FLINT to inhibit and/or treat PF .
• FLINT can be administered acutely at the time of an inflammatory insult to the lung (e.g. during bleomycin treatment) to prevent PF from occurring.
• LIGHT a member of the tumor necrosis factor superfamily, is a ligand of both the Herpes Simplex Virus Entry Mediator (HVEM) and the lymphotoxin beta receptor (D. N. Mauri et al . Immunity, 8, 21-30, 1998) .
• LIGHT is produced primarily by activated T lymphocytes. When LIGHT binds to HVEM on the surface of T cells it stimulates T cell proliferation (J. A. Harrop et al . J. Biol. Chem. 273, 27548-27556, 1998) .
• the present invention relates further to the use of FLINT to bind LIGHT, thereby inhibiting T cell activation.
• T cell activation can be chronically suppressed when advantageous, for example, following organ transplantation to prevent rejection, in the treatment of autoimmune diseases, and in treating systemic inflammatory responses.
• FLINT polypeptide composition will be formulated and dosed in a fashion consistent with good medical practice, taking into account the clinical condition of the individual patient (especially the side effects of treatment with FLINT polypeptide alone) , the site of delivery of the FLINT polypeptide composition, the method of administration, the scheduling of administration, and other factors known to practitioners.
• an effective amount of polypeptide results in a measurable modulation of the biological activity of the selected TNFR family ligand, for example, FasL or LIGHT.
• the biological activity for FasL includes, but is not limited to, apoptosis.
• the biological activity for LIGHT includes, but is not limited to, cell proliferation.
• LIGHT is a 29 kDa type II transmembrane TNF superfamily member protein produced by activated T cells. (Mauri D.M., Immunity, 8:21-30, January 1998).
• an effective amount may also be determined by prevention or amelioration of adverse conditions or symptoms of the diseases or disorders being treated.
• the "therapeutically effective amount" of FLINT polypeptide for purposes herein is thus determined by such considerations.
• FLINT is an immunomodulator and that a common observation with such substances is a bell-shaped dose-response curve. Such a phenomenon is well known in the art and it is within the skill of the clinician to take this into account in adjusting the therapeutically effective amount of FLINT accordingly.
• the total pharmaceutically effective amount of FLINT polypeptide administered parenterally per dose will be in the range of about 1 ⁇ g/kg/day to 10 mg/kg/day of patient body weight, more particularly 2-8mg/kg, preferably 2-4mg/kg, most preferred 2.2mg/kg to 3.3 mg/kg and finally 2.5 mg/kg.
• this dose is at least 0.01 mg/kg/day.
• the FLINT polypeptide is typically administered at a dose rate of about 0.1 ⁇ g/kg/hour to about 50 ⁇ g/kg/hour, either by 1-4 injections per day or by continuous subcutaneous infusions, for example, using a mini-pump.
• An intravenous bag solution may also be employed. The length of treatment needed to observe changes and the interval following treatment for responses to occur appears to vary depending on the desired effect.
• compositions containing the FLINT of the invention may be administered using a variety of modes that include, but are not limited to, oral, rectal, intra- cranial, parenteral, intracisternal, intrathecal, intravaginal, intraperitoneal , intratracheal, intrabronchopulmonary, topical, transdermal (as by powders, ointments, drops or transdermal patch), bucally, or as an oral or nasal spray.
• pharmaceutically acceptable carrier is meant a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type.
• parenteral refers to modes of administration which include but are not limited to, intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion. Implants comprising FLINT also can be used.
• the FLINT polypeptide is also suitably administered by sustained-release systems.
• sustained-release compositions include semi-permeable polymer matrices in the form of shaped articles, e.g., films, or microcapsules .
• Sustained-release matrices include polylactides (U.S. Pat. No. 3,773.919, EP 58,481), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman, U. et al . , Biopolymers 22:547-556 (1983)), poly (2- hydroxyethyl methacrylate) (R.Langer et al . , J. Biomed. Mater . Res .
• Sustained-release FLINT polypeptide compositions also include liposomally entrapped FLINT polypeptides . Liposomes containing FLINT polypeptides are prepared by methods known per se: DE 3,218,121; Epstein et al . , Proc . Natl . Acad. Sci . (USA) 82:3688-3692 (1985); Hwang et al . , Proc. Natl.
• the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent cholesterol, the selected proportion being adjusted for the optimal TNFR polypeptide therapy.
• the FLINT polypeptide is formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable carrier, i.e., one that is non- toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation.
• a pharmaceutically acceptable carrier i.e., one that is non- toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation.
• the formulation preferably does not include oxidizing agents and other compounds that are known to be deleterious to polypeptides .
• the formulations are prepared by contacting the FLINT polypeptide uniformly and intimately with liquid carriers or finely divided solid carriers or both. Then, if necessary, the product is shaped into the desired formulation.
• the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient. Examples of such carrier vehicles include water, saline, Ringer's solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes .
• the carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability.
• additives such as substances that enhance isotonicity and chemical stability.
• Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten residues) polypeptides, e.g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, manose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbi
• the FLINT polypeptide is typically formulated in such vehicles at a concentration of about 0.1 mg/ml to 100 mg/ml, preferably 1-10 mg/ml, at a pH of about 3 to 8. It will be understood that the use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of FLINT polypeptide salts.
• FLINT polypeptides to be used for therapeutic administration must be sterile. Sterility is readily accomplished by filtration through sterile filtration membranes (e.g., 0.2 micron membranes).
• Therapeutic FLINT polypeptide compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.
• FLINT polypeptides ordinarily will be stored in unit or multi-dose containers, for example, sealed ampoules or vials, as an aqueous solution or as a lyophilized formulation for reconstitution.
• a lyophilized formulation 10-ml vials are filled with 5 ml of sterile-filtered 1% (w/v) aqueous FLINT polypeptide solution, and the resulting mixture is lyophilized.
• the infusion solution is prepared by reconstituting the lyophilized FLINT polypeptide using bacteriostatic Water- for-lnjection.
• the invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention.
• Associated with such container (s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.
• the polypeptides of the present invention may be employed in conjunction with other therapeutic compounds .
• the FLINT polypeptides and fusion polypeptides of this invention may be synthesized recombinantly as disclosed in U.S. Patent Application Serial Number 09/280,567 herein incorporated by reference. It often is observed in the production of certain peptides in recombinant systems that expression as a fusion polypeptide prolongs the life span, increases the yield of the desired peptide, or provides a convenient means of purifying the polypeptide. This is particularly relevant when expressing mammalian polypeptides in procaryotic hosts.
• a variety of peptidases e.g. enterokinase and thrombin which cleave a polypeptide at specific sites or digest the peptides from the amino or carboxy termini ( e .
• a variety of amphibian expression systems such as frog oocytes, and mammalian cell systems can be used.
• the choice of a particular host cell depends to some extent on the particular expression vector used.
• Exemplary mammalian host cells suitable for use in the present invention include HepG-2 (ATCC HB 8065), CV-1 (ATCC CCL 70), LC-MK2 (ATCC CCL 7.1), 3T3 (ATCC CCL 92), CH0-K1 (ATCC CCL 61), HeLa (ATCC CCL 2), RPMI8226 (ATCC CCL 155), H4IIEC3 (ATCC CCL 1600), C127I (ATCC CCL 1616), HS- Sultan (ATCC CCL 1484), and BHK-21 (ATCC CCL 10), for example.
• the pSV2-type vectors comprise segments of the simian virus 40 (SV40) genome required for transcription and polyadenylation .
• SV40 simian virus 40
• a large number of plasmid pSV2-type vectors have been constructed, such as pSV2-gpt, pSV2-neo, pSV2-dhfr, pSV2-hyg, and pSV2-»- globin, in which the SV40 promoter drives transcription of an inserted gene.
• Promoters suitable for expression in mammalian cells include the SV40 late promoter, promoters from eucaryotic genes, such as, for example, the estrogen-inducible chicken ovalbumin gene, the interferon genes, the glucocorticoid- inducible tyrosine aminotransferase gene, the thymidine kinase gene promoter, and the promoters of the major early and late adenovirus genes .
• Plasmid pRSVcat (ATCC 37152) comprises portions of a long terminal repeat of the Rous Sarcoma virus, a virus known to infect chickens and other host cells. This long terminal repeat contains a promoter which is suitable for use in the vectors of this invention. H. Gorman et al . , Proc . Nat . Acad. Sci . (USA) , 79, 6777 (1982).
• the plasmid pMSVi (NRRL B-15929) comprises the long terminal repeats of the Murine Sarcoma virus, a virus known to infect mouse and other host cells.
• the mouse metallothionein promoter has also been well characterized for use in eucaryotic host cells and is suitable for use in the present invention.
• This promoter is present in the plasmid pdBPV-MMTneo (ATCC 37224) which can serve as the starting material for the construction of other plasmids of the present invention.
• Transfection of mammalian cells with vectors can be performed by a plurality of well known processes including, but not limited to, protoplast fusion, calcium phosphate co- precipitation, electroporation and the like. See, e . g. , Maniatis et al . , supra .
• viruses also make appropriate vectors. Examples include the adenoviruses , the adeno-associated viruses, the vaccinia virus, the herpes viruses, the baculoviruses , and the Rous sarcoma virus, as described in U.S. Patent 4,775,624, incorporated herein by reference.
• the baculovirus pFastBac-1 (GIBCO/BRL) can be used to infect a suitable host cell, such as SF9, to produce recombinant protein.
• Eucaryotic microorganisms such as yeast and other fungi are also suitable host cells.
• the yeast Sac char omyces cerevisiae is the preferred eucaryotic microorganism.
• Other yeasts such as Kluyveromyces lactis and Pichia pastoris are also suitable.
• the plasmid YRp7 (ATCC-40053) , for example, may be used. See, e . g. , L. Stinchcomb et al . , Nature, 282, 39 (1979); J. Kingsman et al . , Gene, 7, 141 (1979); S. Tschemper et al . , Gene, 10, 157 (1980) .
• Plasmid YRp7 contains the TRP1 gene which provides a selectable marker for use in a trpl auxotrophic mutant.
• RT-PCR Amplification of FLINT Gene from mRNA A FLINT gene is isolated by reverse transcriptase PCR (RT- PCR) using conventional methods. Total RNA from a tissue that expresses the FLINT gene, for example, lung, is prepared using standard methods. First strand FLINT cDNA synthesis is achieved using a commercially available kit (SuperscriptTM System; Life Technologies) by PCR in conjunction with specific primers directed at any suitable region of the FLINT gene (e.g. SEQ ID NO: 2 or SEQ ID NO: 5) .
• Amplification is carried out by adding to the first strand cDNA (dried under vacuum) : 8 ⁇ l of 10X synthesis buffer (200 mM Tris-HCl, pH 8.4; 500 mM KCl, 25 mM MgCl 2 , 1 ug/ul BSA) ; 68 ⁇ l distilled water; 1 ⁇ l each of a 10 uM solution of each primer; and 1 ⁇ l Taq DNA polymerase (2 to 5 U/ ⁇ l) . The reaction is heated at 94° C for 5 minutes to denature the RNA/cDNA hybrid. Then, 15 to 30 cycles of PCR amplification are performed using any suitable thermal cycle apparatus. The amplified sample may be analyzed by agarose gel electrophoresis to check for an appropriately-sized fragment .
• 10X synthesis buffer 200 mM Tris-HCl, pH 8.4; 500 mM KCl, 25 mM MgCl 2 , 1 ug/ul BSA
• EXAMPLE 2 Production of a Vector for Expressing FLINT in a Host Cell
• An expression vector suitable for expressing FLINT or fragment thereof in a variety of procaryotic host cells, such as E. coli is easily made.
• the vector contains an origin of replication (Ori), an ampicillin resistance gene (Amp) useful for selecting cells which have incorporated the vector following a transformation procedure, and further comprises the T7 promoter and T7 terminator sequences in operable linkage to a FLINT coding region.
• Plasmid pETllA obtained from Novogen, Madison WI
• pETllA is linearized by restriction with endonucleases Ndel and BamHI . Linearized pETllA is ligated to a DNA fragment bearing Ndel and BamHI sticky ends and comprising the coding region of the FLINT gene as disclosed by SEQ ID NO : 5.
• the FLINT gene used in this construction may be slightly modified at the 5' end (amino terminus of encoded polypeptide) in order to simplify purification of the encoded polypeptide product.
• an oligonucleotide encoding 8 istidine residues is inserted after the ATG start codon. Placement of the histidine residues at the amino terminus of the encoded polypeptide serves to enable the IMAC one-step polypeptide purification procedure .
• EXAMPLE 3 Recombinant Expression and Purification of FLINT Polypeptide
• An expression vector that carries an open reading frame (ORF) encoding FLINT or fragment thereof and which ORF is operably-linked to an expression promoter is transformed into E. coli BL21 (DE3) (hsdS gal «clts857 indlSam7nin51acUV5-T7gene 1) using standard methods.
• Transformants, selected for resistance to ampicillin, are chosen at random and tested for the presence of the vector by agarose gel electrophoresis using quick plasmid preparations .
• IMAC immobilized metal ion affinity chromatography
• the bound polypeptide is eluted in any suitable buffer at pH 4.3, or preferably with an imidizole-containing buffer at pH 7.5.
• EXAMPLE 4 Construction of Mammalian FLINT-non-Flag Expression Vector
• pIGl-FLINT the 24-base DNA sequence encoding the eight amino acid FLAG epitope was deleted from the pIGl-FLINTF construct using the Quick Change mutagenesis kit (Stratagene) .
• a 35-base primer, and its complement, with identity to the 19-base sequences flanking the FLAG sequence was synthesized and used for PCR amplification using pIGl- FLINTF the plasmid as template.
• the PCR reaction mixture was digested with Dpnl restriction endonuclease to eliminate the parental DNA, and the PCR product was transformed into Epicurean XLI-blue E.
• Dot blot experiment was performed to scan known TNF ligands that are commercially available TRAIL and FasL for interaction with FLINT.
• TRAIL RnD Systems
• FasL Kamiya Biomedical Company
• TRAIL RnD Systems
• FasL Kamiya Biomedical Company
• the filter paper was subsequently blocked for 30 min using 5% nonfat milk in PBS in room temperature.
• the nitrocellulose paper was subsequently mixed with the cell lysate containing FasL-Myc, and further incubated on a rotator for 1 hour at room temperature. Secondary and tertiary incubations were performed with anti-myc antibody and anti-mouse IgG-HRP for 1 hour and 30 minutes respectively.
• the polypeptide containing myc epitope was detected by chemiluminescence on X-ray film which showed that FLINT bound to FasL specifically. No appreciable binding was detected with TNF-, TNF «, TRAIL, CD40L or TRANCE.
• Fas- FasLigand interaction was done for the Fas- FasLigand interaction in vi tro .
• all washing steps use TBST (Tris Buffer Saline with Tween 20 from SIGMA) and were done 3 to 6 times.
• Fas 100 ng was adsorbed on to ELISA plate. Then the plate was is blocked by TBST plus 0.1% Gelatine. Thereafter, FasL (Flag-tagged) was added at different concentrations with a maximum concentration of 300 ng going down to 1 ng on TBST plus a 0.1% solution containing 1 micrograms/ml of M2 Abs (antiflag antibodies purchased through Scientific Imaging System division of Kodak) .
• FLINT-Fas L binding may be confirmed and specifics of binding determined (e . g. , kinetics, specificity, affinity, cooperativity, relative binding pattern, concentration) using real-time biomolecular interaction analysis.
• This technology confers the ability to study biomolecular interactions in real time, without labeling any of the interactants .
• it takes advantage of the optical phenomenon surface plasmon resonance, and detection depends on changes in the mass concentration of macromolecules at the biospecific interface. Interactions are followed in real time, so that kinetic information is readily derived. In many cases, investigations can be performed without prior purification of components.
• Measurements are accomplished using a BiaCore 2000 instrument.
• the instrument, accompanying chips, immobilization and maintenance kits and buffers are obtained from Biacore AB, Rapsgatan 7, S-754 50 Uppsala, Sweden.
• FasL is obtained from Kamiya Biomedical Company, 910 Industry Drive, Seattle, WA 98188, Guanidine Isothiocyanate Solution from GibcoBRL .
• EXAMPLE 8 Measuring the effect of FLINT in a dose-dependent manner on anti-CD3 induced Jurkat apoptosis The same steps for plate coating and cell treatment set out in Example 7 were followed except a different amount of FLINT was added into each well. FLINT was made according to Examples 3. The following table indicates the amounts added : Jurkat cells (Control) 5.33
• EXAMPLE 9 Use of FLINT to Treat ALI Patient A 55 year-old male presents to the emergency department unconscious. His family states that he was being treated as an outpatient for bronchitis for the past few days but worsened despite antibiotics. He has no relevant past history and his only medication was a third generation oral cephalosporin. Physical examination reveals an obtunded, cyanotic male who is hypotensive, tachypneic, and tachycardic, and who has bilateral lung congestion consistent with pulmonary edema. There is no evidence of congestive heart failure. Tests reveal hypoxemia (based on Pa02/Fi02) and bilateral lung infiltrates without cardiomegaly, consistent with a diagnosis of acute lung injury.
• Ventilation measures include use of PEEP and low tidal volume.
• treatment with FLINT is initiated in the ER as an iv bolus of 2.5 mg/kg, followed by a continuous infusion of 0.1 mg/minute.
• FLINT along with aggressive supportive measures (e.g., positive ventilation, intravenous fluids, pressors, and nutritional support) are continued for four days in the ICU, at which time the FLINT is discontinued. Over the following 3 days, the patient begins to recover and is extubated on Day 8. He has an uneventful recovery and 6 months following discharge has no evidence of residual lung disease by blood gas and spirometry .

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Veterinary Medicine (AREA)
• Chemical & Material Sciences (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• General Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Pulmonology (AREA)
• Cell Biology (AREA)
• Zoology (AREA)
• Gastroenterology & Hepatology (AREA)
• Immunology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Epidemiology (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Peptides Or Proteins (AREA)

Applications Claiming Priority (3)

Publications (1)

Family

ID=22577617

Family Applications (1)

Country Status (3)

Families Citing this family (3)

Family Cites Families (3)

• 2000
  • 2000-10-06 WO PCT/US2000/026241 patent/WO2001028582A2/en not_active Application Discontinuation
  • 2000-10-06 AU AU11891/01A patent/AU1189101A/en not_active Abandoned
  • 2000-10-06 EP EP00973379A patent/EP1225908A2/de not_active Withdrawn

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events